The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
The FDA will want to understand this signal fully before approving the drug
Understanding how these medications behave in your system, from initial dosing through to maintenance therapy, helps clarify what to expect during treatment and why gradual dose escalation is standard practice in UK clinical care
Its the first weight-loss medication designed to mimic three of the hormones our bodies produce in response to food at once: GLP-1, GIP, and glucagon
However, sugar-sweetened beverages should be limited due to their glycemic impact
Benefits of GLP-1 Therapy The benefits of GLP-1 therapy extend beyond just controlling blood sugar